Key facts
- It has raised $2.1M.
- Notable investors include MassChallenge, MedTech Innovator, Draper Associates, Berkeley SkyDeck, Berkeley SkyDeck Fund — 10 tracked in total.
- Status: Privately Held (backing).
Investors
10- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for CancerFree Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for CancerFree Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CancerFree Biotech
Developer of a circulating tumor cell-derived organoid platform designed to accurately predict patient responses to cancer therapies. The company has developed a technology based on circulating tumor cells that are like the spreading factor of cancer, which can be cultured and expanded and then used in the self-developed anti-cancer drug detection platform, enabling physicians to identify the most effective treatments and helping pharmaceutical companies develop more effective therapies, ultimately optimizing patient outcomes.
- Sector
- Healthcare
- HQ
- Taipei, Taiwan
- Founded
- 2018
- Employees
- 20
- Website
- cancerfree.io/
- Ownership
- Privately Held (backing)
CancerFree Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CancerFree Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CancerFree Biotech in its N-PORT filings yet. We sweep new filings monthly.